IL-2v was fused to several kinds of mAbs targeting PD-1, carcinoembryonic antigen (CEA), and fibroblast activation protein alpha (FAP) to target PD-1+ T cells, tumor cells, and cancer-associated fibroblasts, respectively. The gene discussed is PDCD1; the disease is cancer.